Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cryofocus Medtech (Shanghai) Co. Ltd. Class H ( (HK:6922) ) has issued an update.
Cryofocus Medtech reported a significant increase in revenue by 162.4% to RMB51.1 million for the first half of 2025, driven by higher sales of its respiratory intervention products. The company’s loss decreased by 51.4% due to strategic optimizations and effective expense control. Notable achievements include the commercialization of the Malignant Stenosis Cryoablation System in China and the designation of the Asthma Cryoablation System as a ‘Breakthrough Medical Device’ by the FDA, enhancing its industry positioning and potential market impact.
More about Cryofocus Medtech (Shanghai) Co. Ltd. Class H
Cryofocus Medtech (Shanghai) Co., Ltd. operates in the medical technology industry, focusing on respiratory intervention products. The company is known for its innovative solutions like the Malignant Stenosis Cryoablation System and Cryoadhesion System, which are designed to address respiratory conditions. The company is actively expanding its market presence, particularly in China, and is recognized for its commitment to research and development in medical devices.
Average Trading Volume: 87,378
Technical Sentiment Signal: Hold
Current Market Cap: HK$1.3B
For an in-depth examination of 6922 stock, go to TipRanks’ Overview page.